LGALS3 and thyroid gland follicular carcinoma: Studies demonstrated the positivities of galectin-3 in 100% of papillary carcinomas, 90–100% of follicular carcinomas, 50–80% of medullary carcinomas, 0–33% of follicular adenomas and 0–38% of nodular goitres (Beesley et al, 2002).